Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3323-3334

  Ki, Min Hyo ^a,b   Kim, Ji Eon ^b   Lee, Young Nam ^a   Noh, Sang Myoung ^a   An, Sung Won ^a   Cho, Hyun Jong ^c   Kim, Dae Duk ^b  

^a Chong Kun Dang Research Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

chitosan; lecithin; nanocomplex; protamine; survivin siRNA; thiamine pyrophosphate

Indexed keywords

ANTINEOPLASTIC AGENT; CHITOSAN; NANOMATERIAL; SMALL INTERFERING RNA;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; MOUSE; NEOPLASMS; PARTICLE SIZE; PROCEDURES; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHITOSAN; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; NEOPLASMS; PARTICLE SIZE; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928974101     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1422-3     Document Type: Article

References (37)

1. Davaa E, Ahn IH, Kang BS, Lee SE, Myung CS, Park JS. Preliminary study to determine the optimal conditions for the simultaneous complexation of siRNA and plasmid DNA. J Pharm Invest. 2013;43:499-505.
2. Wang J, Lu Z, Wientjes MG, Au JL-S. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492-503.
3. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644-70.
4. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-38.
5. Zhang S, Zhao Y, Zhi D, Zhang S. Non-viral vectors for the mediation of RNAi. Bioorg Chem. 2012;40:10-8.
6. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006;58:32-45.
7. Ping Y, Liu C, Zhang Z, Liu KL, Chen J, Li J. Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials. 2011;32:8328-41.
8. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011;21:133-47.
9. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12-27.
10. Malmo J, Hanne S, Vårum KM, Strand SP. SiRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. J Control Release. 2012;158:261-8.
11. Techaarpornkul S, Wongkupasert S, Opanasopit P, Apirakaramwong A, Nunthanid J, Ruktanonchai U. Chitosan-mediated siRNA delivery in vitro: effect of polymer molecular weight, concentration and salt forms. AAPS PharmSciTech. 2010;11:64-72.
12. Park S, Jeong EJ, Lee J, Rhim T, Lee SK, Lee KY. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr Polym. 2013;92:57-62.
13. Fernandes JC, Qiu X, Winnik FM, Benderdour M, Zhang X, Dai K, et al. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomedicine. 2012;7:5833-45.
14. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 2013;34:1270-80.
15. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010;16:3910-22.
16. Malhotra M, Lane C, Tomaro-Duchesneau C, Saha S, Prakash S. A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine. 2011;6:485-94.
17. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011;8:343-57.
18. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146:882-93.
19. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5:487-95.
20. Matsuura M, Yamazake Y, Sugiyama M, Kondo M, Ori H, Nango M, et al. Polycation liposome-mediated gene transfer in vivo. Biochim Biophys Acta. 2003;1612:136-43.
21. Ragelle H, Vandermeulen G, Préat V. Chitosan-based siRNA delivery systems. J Control Release. 2013;172:207-18.
22. Xu S, Dong M, Liu X, Howard KA, Kjems J, Besenbacher F. Direct force measurements between siRNA and chitosan molecules using force spectroscopy. Biophys J. 2007;93:952-9.
23. Doolittle H, Morel A, Talbot D. Survivin-directed anticancer therapies - A review of pre-clinical data and early-phase clinical trials. Eur Oncol. 2010;6:10-4.
24. Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm. 2012;80:257-67.
25. Delgado D, Pozo- Rodríguez A, Solinís MA, Rodríguez-Gascón A. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: The importance of the entry pathway. Eur J Pharm Biopharm. 2011;79:495-502.
26. DeLong RK, Akhtar U, Sallee M, Parker B, Barber S, Zhang J, et al. Characterization and performance of nucleic acid nanoparticles combined with protamine and gold. Biomaterials. 2009;30:6451-9.
27. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 1997;4:891-900.
28. Yuan H, Zhang W, Du Y, Hu F. Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery. Int J Pharm. 2010;392:224-31.
29. Rojanarata T, Opanasopit P, Techaarpornkul S, Ngawhirunpat T, Ruktanonchai U. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res. 2008;25:2807-14.
30. Crawford R, Dogdas B, Keough E, Haas RM, Wepukhulu W, Krotzer S, et al. Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. Int J Pharm. 2011;403:237-44.
31. Mayen V, Wutikhun T, Ketchart O, Kopermsub P. Adsorption of siRNA into mesoporous silica nanoparticles. J Microsc Soc Thai. 2012;5:10-3.
32. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 2011;31:7181-90.
33. Kalsin AM, Kowalczyk B, Smoukov SK, Klajn R, Grzybowski BA. Ionic-like behavior of oppositely charged nanoparticles. J Am Chem Soc. 2006;128:15046-7.
34. Suh MS, Shim G, Lee YH, Han SE, Yu YH, Choi Y, et al. Anionic amino acid-derived cationic lipid for siRNA delivery. J Control Release. 2009;140:268-76.
35. Sternberg B, Hong K, Zheng W, Papahadjopoulos D. Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. Biochim Biophys Acta. 1998;1375:23-35.
36. Han SE, Kang H, Shim GY, Suh MS, Kim SJ, Kim JS, et al. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm. 2008;353:260-9.
37. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6:685-95.